FrancophonIA/ELRC3.0 huggingface dataset:
English: Other information about Libtayo
Estonian: Muu teave Libtayo kohta
English: For more information about using Libtayo, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Libtayo kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Among patients with locally advanced disease who received Libtayo every 2 weeks (at a dose of 3 mg/kg bodyweight) for around 2 years, 44% of patients showed shrinkage of their cancer.
Estonian: Lokaalse kaugelearenenud haigusega patsientidest, kes said Libtayot iga 2 nädala järel (annuses 3 mg kehamassi kg kohta) ligikaudu 2 aasta jooksul, vähenes kasvaja 44%-l.
English: What are the risks associated with Libtayo?
Estonian: Mis riskid Libtayoga kaasnevad?
English: Libtayo is associated with side effects related to the activity of the immune system, which can be serious, although most side effects go away with appropriate treatment or on stopping Libtayo.
Estonian: Libtayot seostatakse immuunsüsteemi aktiivsusega seotud kõrvalnähtudega, mis võivad olla rasked, ehkki suurem osa kõrvalnähtudest kaovad asjakohase raviga või Libtayo võtmise lõpetamisel.
English: Treatment with Libtayo must be started and supervised by a doctor experienced in treating cancer.
Estonian: Ravi Libtayoga peab alustama ja jälgima vähiravis kogenud arst.
English: The company will also investigate whether the medicine works differently depending on the levels of PD-L1 produced by the cancer cells.
Estonian: Turustaja uurib ka seda, kas ravim toime oleneb vähirakkude toodetava PD-L1 tasemest.
English: Since Libtayo has been given conditional authorisation, the company that markets Libtayo will provide data from an ongoing study on the effectiveness and safety of the medicine for cutaneous squamous cell carcinoma.
Estonian: Et Libtayo on saanud müügiloa tingimusliku heakskiidu alusel, esitab Libtayo turustaja andmed praegu toimuvast uuringust ravimi efektiivsuse ja ohutuse kohta naha lamerakk-kartsinoomi korral.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Libtayo have also been included in the summary of product characteristics and the package leaflet.
Estonian: Libtayo ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: How does Libtayo work?
Estonian: Kuidas Libtayo toimib?
English: What information is still awaited for Libtayo?
Estonian: Mis teavet Libtayo kohta veel oodatakse?
English: The company that markets Libtayo will provide a guide and an alert card for patients with information on the signs and symptoms of immune-related side effects of the medicine, as well as instructions on contacting their doctor if they experience symptoms.
Estonian: Libtayo turustaja annab patsientidele juhendi ja ohutuskaardi, millel on ravimi immuunsüsteemiga seotud nähtude ja sümptomite teave, ning juhised võtta sümptomite tekkimisel ühendust arstiga.
English: Libtayo has been given ‘conditional authorisation'.
Estonian: Libtayo on saanud müügiloa tingimusliku heakskiidu alusel.
English: Severe reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis (life-threatening reactions with flu-like symptoms and painful rash affecting the skin, mouth, eyes and genitals) have been reported with Libtayo.
Estonian: Libtayo kasutamisel on teatatud rasketest reaktsioonidest, sealhulgas Stevensi-Johnsoni sündroomist ja toksilisest epidermaalsest nekrolüüsist (eluohtlikud reaktsioonid gripilaadsete sümptomite ja valuliku lööbega nahal, suul, silmades ja suguelunditel).
English: For the full list of side effects and restrictions with Libtayo, see the package leaflet.
Estonian: Libtayo kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: By attaching to the receptor, cemiplimab prevents PD-L1 and PD-L2 from switching off the T cells, thereby increasing the ability of the immune system to kill cancer cells.
Estonian: Retseptoriga seondudes ei lase tsemiplimaab valkudel PD-L1 ja PD-L2 T-rakkude aktiivsust välja lülitada ja suurendab nii immuunsüsteemi võimet hävitada vähirakke.
English: The active substance in Libtayo, cemiplimab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a receptor (target) called PD-1 found on certain cells of the immune system called T cells.
Estonian: Libtayo toimeaine tsemiplimaab on monoklonaalne antikeha ehk teatud valk, mis on kavandatud ära tundma immuunsüsteemi T-rakkude retseptori PD-1 (sihtmärk) ja sellega seonduma.
English: Cancer cells can make proteins (PD-L1 and PD-L2) that attach to this receptor and switch off the activity of the T cells, preventing them from attacking the cancer.
Estonian: Vähirakud toodavad valke PD-L1 ja PD-L2, mis seonduvad selle retseptoriga ja lülitavad välja T-rakkude aktiivsuse, takistades neid vähirakke ründamast.
English: Libtayo is effective at treating cutaneous squamous cell carcinoma in many patients.
Estonian: Libtayo on efektiivne paljude patsientide naha lamerakk-kartsinoomi ravis.
English: What benefits of Libtayo have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Libtayo kasulikkus?
English: Libtayo is a cancer medicine used on its own to treat adults with a type of skin cancer called cutaneous squamous cell carcinoma when the cancer is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body).
Estonian: Libtayo on vähiravim, mida kasutatakse teatud liiki nahavähi, naha lokaalse kaugelearenenud (levinud kõrval olevatele aladele) või metastaatilise (levinud organismis ka mujale) lamerakk-kartsinoomi ainuravimina täiskasvanutel.
English: Libtayo contains the active substance cemiplimab.
Estonian: Libtayo sisaldab toimeainena tsemiplimaabi.
English: Libtayo is given as an infusion (drip) into a vein lasting 30 minutes.
Estonian: Libtayot manustatakse 30 minutit kestva veeniinfusioonina.
English: An overview of Libtayo and why it is authorised in the EU
Estonian: Ülevaade ravimist Libtayo ja ELis müügiloa väljastamise põhjendus
English: How is Libtayo used?
Estonian: Kuidas Libtayot kasutatakse?
English: In the MRP Sweden is the Reference Member State (RMS) and Austria, Belgium, Denmark, Finland, France, Greece, Germany, Italy, Ireland, Luxembourg, The Netherlands, Portugal, Spain and the United Kingdom are Concerned Member States (CMS).
Estonian: Vastastikuse tunnustamise menetluses on viiteliikmesriigiks Rootsi ning asjaomasteks liikmesriikideks Austria, Belgia, Taani, Soome, Prantsusmaa, Kreeka, Saksamaa, Itaalia, Iirimaa, Luksemburg, Madalmaad, Portugal, Hispaania ja Ühendkuningriik.
English: SERETIDE DISKUS and associated names (See Annex I)
Estonian: SERETIDE DISKUS ja sarnaseid nimetusi (vt I lisa)
English: In several EU Member States Seretide Diskus and associated names are approved through the Mutual Recognition Procedure (MRP).
Estonian: Mitmes ELi liikmesriigis on Seretide Diskus ja sarnased nimetused vastastikuse tunnustamise menetluse abil heaks kiidetud.
English: 4 July 2006 EMEA/306065/2006
Estonian: 4. juuli 2006 EMEA/306065/2006
English: Seretide Diskus and associated names (see Annex I) contain salmeterol and fluticasone propionate, a fixed dose combination of the long acting β-agonist salmeterol and the inhaled corticosteroid fluticasone propionate and is indicated for the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: - patients not adequately controlled with inhaled corticosteroids and ‘as needed' inhaled short acting beta-2-agonist or - patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist.
Estonian: Seretide Diskus ja sarnased nimetused (vt I lisa) sisaldavad salmeterooli ja flutikasoonpropionaatipika toimeajaga beetaagonisti salmeterooli ja sissehingatava kortikosteroidi flutikasoonpropionaadi fikseeritud dooside kombinatsiooni, mis on näidustatud astma tavaraviks, kui liittoote (pika toimeajaga beeta2-agonist ja sissehingatav kortikosteroid) kasutamine on asjakohane: patsientidel, kes ei allu hästi ravile sissehingatavate kortikosteroididega ja lühikese toimeajaga vajadusel sissehingatava beeta2agonistiga, või patsientidel, kes alluvad juba tõestatult hästi ravile sissehingatava kortikosteroidi ja pika toimeajaga beeta2-agonistiga manustatuna koos.
English: PERSUANT TO ARTICLE 6(13) OF COMMISSSION REGULATION (EC) No 1084/2003 FOR
Estonian: INIMTERVISHOIUS KASUTATAVATE RAVIMITE KOMITEE TEABEKOKKUVÕTE ARVAMUSEST KOMISJONI MÄÄRUSE (EÜ) 1084/2003 ARTIKLI 6 LÕIKE 13 KOHASE ESILDISE KOHTA, MIS KÄSITLES RAVIMIT
English: This summary was last updated on 12/04/2011.
Estonian: Kokkuvõtte viimane uuendus: 12/04/2011
English: Wash hands after using these products.
Estonian: Pärast ravimi kasutamist tuleb pesta käed.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Veraflox to Bayer Animal Health GmbH on 12/04/2011.
Estonian: Euroopa Komisjon andis Verafloxi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Bayer Animal Health GmbH 12/04/2011.
English: If you need more information about your animal's medical condition or treatment, contact your veterinarian.
Estonian: Kui soovite ravitava looma terviseseisundi või ravi kohta rohkem teavet, võtke palun ühendust oma loomaarstiga.
English: Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP), on the basis of the documentation provided, led to the recommendations on the conditions of use.
Estonian: Selles selgitatakse, kuidas veterinaarravimite komitee hinnangu alusel, mis tugineb esitatud dokumentidele, koostati ravimi kasutustingimuste soovitused.
English: Veraflox 15 mg tablets can be used in both cats and dogs.
Estonian: Verafloxi 15 mg tablette võib kasutada nii kassidel kui ka koertel.
English: If Veraflox is swallowed accidentally, seek medical advice immediately and show the package leaflet or the label to the doctor.
Estonian: Verafloxi juhusliku allaneelamise korral pöörduge kohe arsti poole ja näidake ravimi pakendi infolehte või etiketti.
English: The studies showed that Veraflox was at least as effective as the comparator medicines in all indications.
Estonian: Uuringutes leiti, et Veraflox oli kõigi näidustuste puhul vähemalt sama efektiivne kui võrdlusravimid.
English: What is the risk associated with Veraflox?
Estonian: Mis riskid Verafloxiga kaasnevad?
English: It is available as brownish tablets containing 15 mg, 60 mg or 120 mg pradofloxacin, and as a yellowish/beige coloured oral suspension, containing 25 mg/ml pradofloxacin.
Estonian: Seda turustatakse pruunikate tablettidena, mis sisaldavad 15 mg, 60 mg või 120 mg pradofloksatsiini, ning kollakas-beeži värvusega suukaudse suspensioonina, mis sisaldab pradofloksatsiini 25 mg/ml.
English: By blocking two enzymes called ‘DNA gyrase' and ‘topoisomerase IV', pradofloxacin stops the bacteria from growing and multiplying.
Estonian: Kaht ensüümi (DNA-güraas ja topoisomeraas-IV) blokeerides takistab pradofloksatsiin bakterite arengut ja paljunemist.
English: The dose and duration of treatment depend on the species of the animal being treated and its body weight, the nature and severity of the infection, and the animal's response to the treatment.
Estonian: Annus ja ravi kestus sõltuvad ravitava looma liigist ja kehakaalust, infektsiooni liigist ja raskusastmest ning looma ravivastusest.
English: Veraflox must not be used in young growing dogs, in kittens below 6 weeks of age, in animals with joint problems caused by damage to the cartilage, or in animals with central nervous system disorders such as epilepsy.
Estonian: Verafloxi ei tohi kasutada koerakutsikatel kasvuperioodil, alla 6-nädalastel kassipoegadel, kõhrkoe kahjustusest põhjustatud liigesevaevustega loomadel või loomadel, kellel on kesknärvisüsteemi häired, nagu epilepsia.
English: The 60 mg and 120 mg tablets are only for use for dogs, and Veraflox oral suspension is only for use in cats.
Estonian: 60 mg ja 120 mg tabletid on ette nähtud kasutamiseks üksnes koertel ning Verafloxi suukaudne suspensioon kasutamiseks kassidel.
English: Veraflox must not be used in animals that may be hypersensitive (allergic) to fluoroquinolone antibiotics.
Estonian: Verafloxi ei tohi kasutada loomadel, kes võivad olla fluorokinoloonide rühma kuuluvate antibiootikumide suhtes ülitundlikud (allergilised).
English: Veraflox is a medicine that contains pradofloxacin.
Estonian: Veraflox on pradofloksatsiini sisaldav ravim.
English: The company presented the results of studies looking at the effectiveness of Veraflox against a range of bacterial infections in cats and dogs.
Estonian: Ettevõte esitas uuringute tulemused, milles analüüsiti Verafloxi efektiivsust kassidel ja koertel esinevate mitmesuguste bakteriaalsete infektsioonide korral.
English: It can also be used in conjunction with dental treatment in dogs with severe gum infections.
Estonian: Samuti võib seda kasutada kaasneva ravina raske igemete infektsiooniga koerte hambaravi korral.
English: In all of the studies the effectiveness of Veraflox was compared with antibiotics that are commonly used for the treatment of the infections studied (amoxicillin with or without clavulanic acid for the skin and urinary tract infections, and clindamycin for the gum infections).
Estonian: Kõigis uuringutes võrreldi Verafloxi efektiivsust asjaomaste infektsioonide ravis tavapäraselt kasutatavate antibiootikumide efektiivsusega (naha- ja kuseteede infektsioonide korral amoksitsilliin monoteraapiana või kombinatsioonis klavulaanhappega; igemete infektsioonide korral klindamütsiin).
English: In case of contact, rinse immediately with plenty of water.
Estonian: Kui see juhtub, tuleb ravimiga kokku puutunud kohta rohke veega loputada.
English: People who are hypersensitive (allergic) to quinolone antibiotics should avoid any contact with Veraflox.
Estonian: Kinoloonantibiootikumide suhtes ülitundlikud (allergilised) inimesed peavad kokkupuudet Verafloxiga vältima.
English: Why has Veraflox been approved?
Estonian: Miks Veraflox heaks kiideti?
English: Other information about Veraflox:
Estonian: Muu teave Verafloxi kohta
English: The most common side effects in dogs and cats are mild transient gastro-intestinal disturbances including vomiting, although these have only been observed rarely.
Estonian: Koerte ja kasside kõige sagedamad kõrvalnähud on kerged mööduvad seedehäired, sealhulgas oksendamine, kuigi neid on täheldatud vaid harvadel juhtudel.
English: For the oral suspension it is 5 mg pradofloxacin per kilogram body weight once a day.
Estonian: Suukaudse suspensiooni puhul on annus 5 mg pradofloksatsiini kehakaalu kilogrammi kohta ööpäevas.
English: How has Veraflox been studied?
Estonian: Kuidas Verafloxi uuriti?
English: The standard dose for tablets is 3 mg pradofloxacin per kilogram body weight once a day.
Estonian: Tablettide puhul on tavapärane annus 3 mg pradofloksatsiini kehakaalu kilogrammi kohta ööpäevas.
English: Therefore all products should be kept out of the reach and sight of children.
Estonian: Seetõttu tuleb ravimit hoida lastele kättesaamatus kohas.
English: The active substance in Veraflox, pradofloxacin, belongs to a group of antibiotics called ‘fluoroquinolones'.
Estonian: Verafloxi toimeaine pradofloksatsiin on fluorokinoloonide hulka kuuluv antibiootikum.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Veraflox exceed the risks for the treatment of certain specified infections in dogs and cats and recommended that Veraflox be given a marketing authorisation.
Estonian: Veterinaarravimite komitee otsustas, et Verafloxi kasulikkus kassidel ja koertel esinevate teatud infektsioonide ravis on suurem kui sellega kaasnevad riskid.
English: Veraflox must not be used in female animals that are pregnant or lactating.
Estonian: Verafloxi ei tohi kasutada emastel loomadel tiinuse ja imetamise perioodil.
English: More information on the benefit-risk balance can be found in the Scientific Discussion part of this EPAR.
Estonian: Ravimi kasulikkuse ja riski suhe on käesoleva Euroopa avaliku hindamisaruande teaduslikku arutelu käsitlevas jaotises.
English: People should ensure that Veraflox does not come into contact with their skin or eyes.
Estonian: Tuleb hoida ära Verafloxi sattumine silma ja nahale.
English: Do not eat, drink or smoke while handling Veraflox products.
Estonian: Verafloxi valmististe käsitsemisel ei tohi süüa, juua ega suitsetada.
English: In addition, the oral suspension can also be used to treat some skin infections, including wound infections and abscesses, caused by certain specific bacteria.
Estonian: Suukaudset suspensiooni võib samuti kasutada teatud nahainfektsioonide, sealhulgas haavainfektsioonide ja abstsesside raviks, mida põhjustavad teatud spetsiifilised bakterid.
English: What is Veraflox used for?
Estonian: Milleks Verafloxi kasutatakse?
English: For more information see the package leaflet.
Estonian: Üksikasjalik teave on pakendi infolehel.
English: The full list of bacteria against which Veraflox is active can be found in the Summary of Product Characteristics (SPC).
Estonian: Verafloxi suhtes tundlike bakterite täielik loetelu on esitatud ravimi omaduste kokkuvõttes.
English: Pradofloxacin
Estonian: Veraflox pradofloksatsiin
English: Pradofloxacin works by blocking some of the enzymes that are important in allowing bacteria to make copies of their DNA.
Estonian: Pradofloksatsiin blokeerib teatud bakterite DNA replikatsiooni toetavad ensüümid.
English: Veraflox products can be harmful to children if they are accidentally swallowed.
Estonian: Juhusliku allaneelamise korral võivad Verafloxi valmistised kujutada ohtu lastele.
English: Veraflox is well tolerated in cats and dogs with mild transient gastro-intestinal disturbances, including vomiting, being observed only in rare cases.
Estonian: Kassid ja koerad taluvad Verafloxi hästi, kusjuures harvadel juhtudel on täheldatud kergeid mööduvaid seedehäireid, sealhulgas oksendamist.
English: What benefit has Veraflox shown during the studies?
Estonian: Milles seisneb uuringute põhjal Verafloxi kasulikkus?
English: In dogs, Veraflox is used to treat some skin infections, including wound infections, and acute urinary tract infections caused by certain specific bacteria.
Estonian: Koertel kasutatakse Verafloxi teatud nahainfektsioonide (sealhulgas haavainfektsioonide) ning kuseteede ägedate infektsioonide raviks, mida põhjustavad teatud spetsiifilised bakterid.
English: In cats, Veraflox is used to treat acute infections of the upper respiratory tract caused by certain specific bacteria.
Estonian: Kassidel kasutatakse Verafloxi ülemiste hingamisteede ägedate infektsioonide raviks, mida põhjustavad teatud spetsiifilised bakterid.
English: In cats, the medicine was studied in acute infections of the upper respiratory tract and also some skin infections caused by certain specific bacteria.
Estonian: Kassidel uuriti ravimit ülemiste hingamisteede ägedate infektsioonide ja nahainfektsioonide puhul, mida põhjustavad teatud spetsiifilised bakterid.
English: In dogs, the medicine was studied in some skin, urinary tract and gum infections caused by certain specific bacteria.
Estonian: Koertel uuriti ravimit naha-, kuseteede ja igemete infektsioonide puhul, mida põhjustavad teatud spetsiifilised bakterid.
English: How does Veraflox work?
Estonian: Kuidas Veraflox toimib?
English: This summary was last updated in 09- 2011.
Estonian: Kokkuvõtte viimane uuendus: 09-2011.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Viramune on 5 February 1998.
Estonian: Euroopa Komisjon andis Viramune müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 5. Veebruaril 1998.
English: The full EPAR for Viramune can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Viramune kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Similar results were seen in HIV-1-infected children.
Estonian: HIV-1-nakkusega lastel täheldati sarnaseid tulemusi.
English: As the company had supplied the additional information requested, the ‘exceptional circumstances' ended on 11 July 2002.
Estonian: Et ettevõte esitas vajaliku lisateabe, tühistati müügiloa erandkorras väljastatus 11. juulil 2002.
English: Other information about Viramune
Estonian: Muu teave Viramune kohta
English: The prolonged-release tablets have not been tested in children under 3 years of age.
Estonian: Toimeainet prolongeeritult vabastavate tablettide toimet ei ole uuritud alla 3-aastastel lastel.
English: Viramune does not cure HIV-1 infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Estonian: Viramune ei ravi HIV-1-nakkust ega AIDSi välja, kuid võib immuunsüsteemi kahjustumise ja AIDSiga seotud nakkuste ja haiguste tekke edasi lükata.
English: The Committee recommended that Viramune be given marketing authorisation.
Estonian: Komitee soovitas anda Viramunele müügiloa.
English: The prolonged-release tablets must not be broken or chewed.
Estonian: Toimeainet prolongeeritult vabastavaid tablette ei tohi murda ega närida.
English: Viramune was originally authorised under ‘exceptional circumstances', because, for scientific reasons, limited information was available at the time of the approval.
Estonian: Viramune müügiluba anti esialgu erandkorras, sest teaduslikel põhjustel ei olnud ravimi heakskiitmise ajal olemas selle kohta piisavalt teavet.
English: What is Viramune?
Estonian: Mis on Viramune?
English: Viramune, taken alone or in combination with one or two other antiviral medicines, has also been studied in two studies including 478 children.
Estonian: Viramune toimet kasutamisel ainsa ravimina või koos ühe või kahe muu viiruseravimiga uuriti kahes uuringus, milles osales 478 last.
English: If the patient cannot switch to the full dose within four weeks of starting Viramune, alternative treatments should be sought.
Estonian: Kui patsient ei saa Viramune võtmise algusest 4 nädala jooksul üle minna täisannusele, tuleb kaaluda muid ravivõimalusi.
English: It is used in combination with other antiviral medicines to treat patients infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: Seda kasutatakse koos teiste viiruseravimitega nende patsientide raviks, kellel on inimese 1. tüüpi immuunpuudulikkuse viiruse (HIV-1) nakkus, mis põhjustab omandatud immuunpuudulikkuse sündroomi (AIDS).
English: CD4 T-cells are white blood cells that are important in helping to fight infections but which are killed by HIV.
Estonian: CD4-T-rakud on leukotsüüdid (valgelibled), mis aitavad oluliselt nakkuste vastu võidelda, kuid mida HIV hävitab.
English: Patients should be monitored closely for signs of these side effects during the first 18 weeks of treatment, and blood tests for liver problems should be carried out regularly throughout treatment.
Estonian: Patsiente tuleb esimese 18 ravinädala jooksul nende kõrvalnähtude suhtes hoolikalt jälgida ning teha kogu ravi kestel maksakahjustuste avastamiseks regulaarselt vereanalüüse.
English: In 151 treatment-naïve patients (who had not taken treatment for HIV infection before), viral load fell by 99% in the three-medicine group, compared with 96% in the two-medicine group after 40 to 52 weeks.
Estonian: 151 varem ravimata patsiendil (kellel ei olnud HIV-nakkust varem ravitud) vähenes viiruskoormus 40-52 nädalaga kolme ravimiga rühmas 99% võrra ning kahe ravimiga rühmas 96% võrra.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Viramune.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.